アブストラクト | BACKGROUND: Daptomycin is a lipopeptide antibiotic with a broad spectrum of activity against gram-positive bacteria. Although information on daptomycin-induced adverse events can be found in clinical trials, data regarding the impact of age on these events are insufficient. Therefore, we evaluated whether age affects the occurrence of daptomycin-induced adverse events using adverse drug event reports in post-marketing stages provided by the U.S. Food and Drug Administration (FDA). METHODS: A total dataset of 7307 reports of patients treated with daptomycin in the FDA's Adverse Event Reporting System were analyzed. The patients were divided into seven age groups: 0-28 days, >28 days-23 months, 2-11 years, 12-17 years, 18-64 years, 65-80 years, and >80 years. A disproportionality analysis was conducted to calculate the reporting odds ratio, with a 95 % confidence interval. The univariate regression analysis was conducted using the percentage of each adverse event and age groups. RESULTS: Compared with the number of reports aged 18-64 years, there were significantly increased reports of eosinophilic pneumonia in patients aged 65-80 years and >80 years, anaphylactic reaction and pseudomembranous colitis in patients aged 12-17 years, and acute renal failure in patients aged 65-80 years. The regression coefficient for the reporting proportion of eosinophilic pneumonia was significantly positive. CONCLUSIONS: Our findings revealed age-related trends in daptomycin-induced adverse events, supporting the idea that implementing age-dependent follow-up and supportive care helps in the continuation of daptomycin therapy. |
ジャーナル名 | Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy |
投稿日 | 2024/8/31 |
投稿者 | Shiraishi, Chihiro; Kato, Hideo; Ogura, Toru; Iwamoto, Takuya |
組織名 | Department of Pharmacy, Mie University Hospital, Mie, Japan; Department of;Clinical Pharmaceutics, Division of Clinical Medical Science, Mie University;Graduate School of Medicine, Mie, Japan.;Graduate School of Medicine, Mie, Japan. Electronic address:;hkato59@med.mie-u.ac.jp.;Clinical Research Support Center, Mie University Hospital, Mie, Japan. |
Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/39209260/ |